Exponent CEO granted 28,500 stock options

Corrigan Catherine reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Corrigan Catherine reported acquisition or exercise transactions in this Form 4 filing.

Exponent Inc. President and CEO Catherine Corrigan reported awards of stock options, increasing her potential equity exposure to the company. She received 1,425 Incentive Stock Options and 27,075 Non-Qualified Stock Options, both granted at no cost as part of her compensation.

According to the disclosure, each stock option grant becomes exercisable in four equal annual installments, meaning the rights vest gradually over four years rather than all at once. These are options giving her the right to buy shares in the future; they are not immediate stock purchases or sales.

Insider Trade Summary

Grant/Award: 28,500 shares

Grant/Award 2 txns

Insider Corrigan Catherine

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Incentive Stock Option (right to buy)	1,425	$0.00	$0.00
Grant/Award	Non-Qualified Stock Option (right to buy)	27,075	$0.00	$0.00

Holdings After Transaction: Incentive Stock Option (right to buy) — 1,425 contracts (Direct); Non-Qualified Stock Option (right to buy) — 27,075 contracts (Direct)

Footnotes (2)

1. F1. The stock option becomes exercisable in four equal annual installments.
2. F2. Not applicable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Exponent (EXPO) report for Catherine Corrigan?

Exponent reported that President and CEO Catherine Corrigan received grants of stock options. She was awarded 1,425 Incentive Stock Options and 27,075 Non-Qualified Stock Options, giving her rights to purchase shares in the future under specified terms.

How many stock options did the Exponent (EXPO) CEO receive in this Form 4?

Catherine Corrigan received a total of 28,500 stock options. The award includes 1,425 Incentive Stock Options and 27,075 Non-Qualified Stock Options, all recorded as derivative securities that may be exercised for Exponent common stock over time.

Are the Exponent (EXPO) CEO’s new stock options immediately exercisable?

No, the options are not immediately exercisable. The filing states that each stock option grant becomes exercisable in four equal annual installments, creating a four-year vesting schedule that gradually increases the CEO’s ability to exercise these options.

Did Catherine Corrigan buy or sell Exponent (EXPO) shares in this filing?

She did not buy or sell common shares in the market. The Form 4 shows an acquisition of derivative securities through option grants, recorded with transaction code “A” for grant or award, at a reported price of $0.0000 per option.

What types of stock options were granted to the Exponent (EXPO) CEO?

The CEO received two types of stock options. One grant is labeled “Incentive Stock Option (right to buy)” for 1,425 options, and the other is “Non-Qualified Stock Option (right to buy)” for 27,075 options, both held directly in her name.

How is Catherine Corrigan’s ownership reported after the Exponent (EXPO) option grants?

After the grants, the filing shows 1,425 Incentive Stock Options and 27,075 Non-Qualified Stock Options held directly. These figures represent derivative securities outstanding following the transactions, reflecting her potential future right to acquire Exponent common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 06:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corrigan Catherine

(Last) (First) (Middle)

149 COMMONWEALTH DRIVE

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXPONENT INC [ EXPO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)	$70.16	02/20/2026		A		1,425		(1)	02/20/2036	Common Stock	1,425	(2)	1,425	D
Non-Qualified Stock Option (right to buy)	$70.16	02/20/2026		A		27,075		(1)	02/20/2036	Common Stock	27,075	(2)	27,075	D

Explanation of Responses:

1. The stock option becomes exercisable in four equal annual installments.

2. Not applicable.

	By: Wendy Whitehouse For: Catherine Corrigan	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.